MMRF CoMMpass STUDY YI
SM
Since its start in 2011, The MMRF
CoMMpass Study SM has revolutionized
how research is done in the field of
multiple myeloma. This publically
available data set has allowed
researchers all over the world to
collaborate in order to speed up the rate
of discoveries about myeloma and the
development of new treatments. When
data is shared, patients benefit.
Our goal is to gather as much data about
multiple myeloma as we can, to answer
questions about myeloma care and
treatment facing the community. We
have enrolled more than 1,150 patients
from 90 clinical sites in four countries
in CoMMpass, and we now have the
largest genomic data set in all of cancer.
This ensures that we’re learning as
much about myeloma as we can and are
helping as many patients as possible.
SOME OF THE THINGS WE’VE LEARNED ALREADY AS A RESULT OF CoMMpass
THREE MEDICATIONS ARE
BETTER THAN TWO STEM CELL
TRANSPLANT WORKS THERE ARE 12 TYPES
OF MYELOMA
Patients who take three medications
(called triplet therapy) have a longer
period of remission before their
disease comes back than patients
who take two. Triplet therapy plus stem cell
transplant shows better results
than triplet therapy alone. We’ve identified 12 different
molecular types of myeloma, each
with its own challenges and best
treatments. This is helping patients get
the right treatment at the right time.
WHAT’S NEXT?
We’ve only just begun. The next step
is to study more patients and identify
more types of myeloma. At this year’s
American Society of Hematology (ASH)
annual meeting in Atlanta, the MMRF
4
was part of more than 30 presentations,
26 of them a direct result of CoMMpass.
From looking at survival after stem
cell transplant to identifying genetic
mutations in tumors that can be targets
for treatment, the data collected as a
part of the CoMMpass Study is yielding
results that move us closer to our goal of
precisely the right treatment at the right
time for every patient.
T H E M M R F.ORG